Mesutoclax not checked
Beijing InnoCare Pharma Tech Co., Ltd. · ICP-248
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Eligible patients will receive ICP-248 orally as per the protocol”In the company’s words, NCT07896590 on ClinicalTrials.gov
- Tested for
- Relapsed or Refractory Mantle Cell Lymphoma (MCL) (2 trials), Relapsed/Refractory Marginal Zone Lymphoma (MZL), Acute Myeloblastic Leukemia, Hematologic Malignancies, Hematological Malignancies, Mature B-cell Malignancies, Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)
- Main trialPhase 3
- “To evaluate the efficacy of olubrutinib combined with ICP-248 compared with the olubrutinib in the treatment of r/r MZL”In the company’s words, NCT07896590 on ClinicalTrials.gov
- Other names
- ICP-248
Other drugs for Relapsed or Refractory Mantle Cell Lymphoma (MCL)
- DostarlimabGSK · Phase 3
- NiraparibGSK · Phase 3
- MezigdomideCelgene · Phase 3
- PlonmarlimabTJ Biopharma Co., Ltd. · Phase 3
- GumarontinibCSPC · Phase 2/3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
Coming up7
- 25 Jun 2027Phase 1 trial completes · ClinicalTrials.gov
- Jun 2027Phase 1 trial completes · ClinicalTrials.gov
- Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- Oct 2028Phase 3 trial completes · ClinicalTrials.gov
- Dec 2029Phase 3 trial completes · ClinicalTrials.gov
- 25 Nov 2030Phase 2/3 trial completes · ClinicalTrials.gov
- Oct 2032Phase 3 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 13 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT07925190
- 9 NovNew trial: none to Phase 3 · ClinicalTrials.gov NCT07925190
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Oct 2028 | Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma | |
| Phase 3Recruiting | Dec 2029 | A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients | |
| Phase 3Not yet recruiting | Oct 2032 | A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL). | |
| Phase 2/3Recruiting | 25 Nov 2030 | ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03) | |
| Phase 2Recruiting | Dec 2027 | A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06) | |
| Phase 1Recruiting | 30 Aug 2025 | The Study of ICP-248 in Patients With Mature B-cell Malignancies | |
| Phase 1Recruiting | 25 Jun 2027 | Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies | |
| Phase 1Recruiting | Jun 2027 | ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026